Clinical Trials Directory

Trials / Completed

CompletedNCT01194375

A Dose-Ranging Study Evaluating the Safety and Efficacy of IDP-107 in Patients With Acne Vulgaris

Status
Completed
Phase
Phase 2
Study type
Interventional
Enrollment
180 (actual)
Sponsor
Dow Pharmaceutical Sciences · Industry
Sex
All
Age
12 Years
Healthy volunteers
Not accepted

Summary

The purpose of this study is to evaluate the safety and efficacy of IDP-107 versus placebo in treating patients with acne vulgaris.

Conditions

Interventions

TypeNameDescription
DRUGLow Strength IDP-107Once a day for 16 weeks
DRUGHigh Strength IDP-107Once a day for 16 weeks
DRUGPlaceboOnce a day for 16 weeks

Timeline

Start date
2010-09-01
Primary completion
2011-12-01
Completion
2011-12-01
First posted
2010-09-03
Last updated
2012-07-02

Locations

20 sites across 2 countries: United States, Canada

Source: ClinicalTrials.gov record NCT01194375. Inclusion in this directory is not an endorsement.

A Dose-Ranging Study Evaluating the Safety and Efficacy of IDP-107 in Patients With Acne Vulgaris (NCT01194375) · Clinical Trials Directory